{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,23]],"date-time":"2025-10-23T10:54:39Z","timestamp":1761216879649},"reference-count":51,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2005,3]]},"DOI":"10.1097\/01.hpc.0000155219.26524.19","type":"journal-article","created":{"date-parts":[[2005,2,25]],"date-time":"2005-02-25T09:03:25Z","timestamp":1109322205000},"page":"10-20","source":"Crossref","is-referenced-by-count":13,"title":["B-Type Natriuretic Peptide in Heart Failure"],"prefix":"10.1097","volume":"4","author":[{"given":"Mandeep R.","family":"Mehra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alan","family":"Maisel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-3-20210119","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1001\/archinte.1997.00440220103013","article-title":"Readmission after hospitalization for congestive heart failure among Medicare beneficiaries.","volume":"157","author":"Krumholz","year":"1997","journal-title":"Arch Intern Med"},{"issue":"suppl III","key":"R3-3-20210119","first-page":"III","article-title":"The economic burden of heart failure.","volume":"23","author":"O'Connell","year":"2000","journal-title":"Clin Cardiol"},{"issue":"suppl 7","key":"R4-3-20210119","first-page":"S21","article-title":"The Acute Decompensated Heart Failure National Registry (ADHERE): opportunities to improve care of patients hospitalized with acute decompensated heart failure.","volume":"4","author":"Fonarow","year":"2003","journal-title":"Rev Cardiovasc Med"},{"issue":"suppl 1","key":"R5-3-20210119","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1527-5299.2004.03310.x","article-title":"B-type natriuretic peptide: the level and the drug\u2013partners in the diagnosis of congestive heart failure.","volume":"10","author":"Bhalla","year":"2004","journal-title":"Congest Heart Fail"},{"key":"R6-3-20210119","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1161\/01.CIR.0000109205.35813.8E","article-title":"Should B-type natriuretic peptide be measured routinely to guide the diagnosis and management of chronic heart failure?","volume":"108","author":"Packer","year":"2003","journal-title":"Circulation"},{"key":"R7-3-20210119","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.pharmthera.2004.04.004","article-title":"Implications of the natriuretic peptide system in the pathogenesis of heart failure: diagnostic and therapeutic importance.","volume":"102","author":"Abassi","year":"2004","journal-title":"Pharmacol Ther"},{"key":"R8-3-20210119","doi-asserted-by":"crossref","first-page":"1280","DOI":"10.1172\/JCI118162","article-title":"Rapid transcriptional activation and early mRNA turnover of brain natriuretic peptide in cardiocyte hypertrophy. Evidence for brain natriuretic peptide as an \u2018emergency\u2019 cardiac hormone against ventricular overload.","volume":"96","author":"Nakagawa","year":"1995","journal-title":"J Clin Invest"},{"key":"R9-3-20210119","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S0002-8703(98)70041-9","article-title":"Plasma brain natriuretic peptide as a biochemical marker of high left ventricular end-diastolic pressure in patients with symptomatic left ventricular dysfunction.","volume":"135","author":"Maeda","year":"1998","journal-title":"Am Heart J"},{"key":"R10-3-20210119","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1006\/bbrc.1995.2410","article-title":"The amino-terminal portion of pro-brain natriuretic peptide (pro-BNP) circulates in human plasma.","volume":"214","author":"Hunt","year":"1995","journal-title":"Biochem Biophys Res Commun"},{"key":"R11-3-20210119","first-page":"72","article-title":"B-type natriuretic peptides: a diagnostic breakthrough for clinicians.","volume":"4","author":"McCullough","year":"2003","journal-title":"Rev Cardiovasc Med"},{"key":"R12-3-20210119","doi-asserted-by":"crossref","first-page":"1781","DOI":"10.1016\/S0735-1097(01)01269-4","article-title":"Plasma N-terminal pro-brain natriuretic peptide and adrenomedullin: prognostic utility and prediction of benefit from carvedilol in chronic ischemic left ventricular dysfunction Australia\u2013New Zealand Heart Failure Group.","volume":"37","author":"Richards","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"suppl 3","key":"R13-3-20210119","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-5299.2004.03271.x","article-title":"BNP Consensus Panel 2004: A clinical approach for the diagnostic, prognostic, screening, treatment monitoring, and therapeutic roles of natriuretic peptides in cardiovascular diseases.","volume":"10","author":"Silver","year":"2004","journal-title":"Congest Heart Fail"},{"key":"R14-3-20210119","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1054\/jcaf.2001.24609","article-title":"B-type natriuretic peptide levels: a potential novel \u201cwhite count\u201d for congestive heart failure.","volume":"7","author":"Maisel","year":"2001","journal-title":"J Card Fail"},{"key":"R15-3-20210119","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1080\/00365519909168337","article-title":"Natriuretic peptides in assessment of left-ventricular dysfunction.","volume":"230","author":"Mair","year":"1999","journal-title":"Scand J Clin Lab Invest Suppl"},{"key":"R16-3-20210119","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.cccn.2003.10.026","article-title":"The effect of class-specific protease inhibitors on the stabilization of B-type natriuretic peptide in human plasma.","volume":"340","author":"Belenky","year":"2004","journal-title":"Clin Chim Acta"},{"key":"R17-3-20210119","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/S0009-8981(01)00578-2","article-title":"Head-to-head comparison of N-terminal pro-brain natriuretic peptide, brain natriuretic peptide and N-terminal pro-atrial natriuretic peptide in diagnosing left ventricular dysfunction.","volume":"310","author":"Hammerer-Lercher","year":"2001","journal-title":"Clin Chim Acta"},{"key":"R18-3-20210119","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1016\/j.ehj.2003.07.005","article-title":"N-terminal pro-brain natriuretic peptide. A new gold standard in predicting mortality in patients with advanced heart failure.","volume":"24","author":"Gardner","year":"2003","journal-title":"Eur Heart J"},{"key":"R19-3-20210119","doi-asserted-by":"crossref","first-page":"2392","DOI":"10.1161\/01.CIR.0000016642.15031.34","article-title":"B-type natriuretic peptide predicts sudden death in patients with chronic heart failure.","volume":"105","author":"Berger","year":"2002","journal-title":"Circulation"},{"key":"R20-3-20210119","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1136\/heart.86.1.21","article-title":"Left ventricular function, natriuretic peptides, and mortality in an urban population.","volume":"86","author":"McDonagh","year":"2001","journal-title":"Heart"},{"key":"R21-3-20210119","first-page":"H1049","article-title":"Coronary vasodilator effects of BNP: mechanisms of action in coronary conductance and resistance arteries.","volume":"276","author":"Zellner","year":"1999","journal-title":"Am J Physiol"},{"key":"R22-3-20210119","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/S0735-1097(01)01172-X","article-title":"Effects of intravenous brain natriuretic peptide on regional sympathetic activity in patients with chronic heart failure as compared with healthy control subjects.","volume":"37","author":"Brunner-La Rocca","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R23-3-20210119","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S1071-9164(98)90506-1","article-title":"Systemic hemodynamic, neurohormonal, and renal effects of a steady-state infusion of human brain natriuretic peptide in patients with hemodynamically decompensated heart failure.","volume":"4","author":"Abraham","year":"1998","journal-title":"J Card Fail"},{"key":"R24-3-20210119","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9149(02)02507-9","article-title":"Intravenous nesiritide (human B-type natriuretic peptide) reduces plasma endothelin-1 levels in patients with decompensated congestive heart failure.","volume":"90","author":"Aronson","year":"2002","journal-title":"Am J Cardiol"},{"key":"R25-3-20210119","first-page":"R1077","article-title":"BNP: pathophysiological and potential therapeutic roles in acute congestive heart failure.","volume":"272","author":"Grantham","year":"1997","journal-title":"Am J Physiol"},{"key":"R26-3-20210119","doi-asserted-by":"crossref","first-page":"S277","DOI":"10.1016\/S1071-9164(96)80088-1","article-title":"Natriuretic peptides in the treatment of heart failure.","volume":"2","author":"Yasue","year":"1996","journal-title":"J Card Fail"},{"key":"R27-3-20210119","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1056\/NEJM200007273430403","article-title":"Intravenous nesiritide, a natriuretic peptide, in the treatment of decompensated congestive heart failure Nesiritide Study Group.","volume":"343","author":"Colucci","year":"2000","journal-title":"N Engl J Med"},{"key":"R28-3-20210119","doi-asserted-by":"crossref","first-page":"1581","DOI":"10.1161\/01.CIR.84.4.1581","article-title":"Hemodynamic, renal, and hormonal responses to brain natriuretic peptide infusion in patients with congestive heart failure.","volume":"84","author":"Yoshimura","year":"1991","journal-title":"Circulation"},{"key":"R29-3-20210119","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1139\/y01-039","article-title":"Pathophysiological significance and clinical application of ANP and BNP in patients with heart failure.","volume":"79","author":"Yoshimura","year":"2001","journal-title":"Can J Physiol Pharmacol"},{"key":"R30-3-20210119","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1016\/S0002-8703(98)70054-7","article-title":"Natriuretic peptides: physiology, therapeutic potential, and risk stratification in ischemic heart disease.","volume":"135","author":"Stein","year":"1998","journal-title":"Am Heart J"},{"key":"R31-3-20210119","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/0024-3205(88)90113-0","article-title":"Intrarenal localization of degradation of atrial natriuretic peptide in isolated glomeruli and cortical nephron segments.","volume":"43","author":"Shima","year":"1988","journal-title":"Life Sci"},{"key":"R32-3-20210119","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1677\/joe.0.1670239","article-title":"Delayed metabolism of human brain natriuretic peptide reflects resistance to neutral endopeptidase.","volume":"167","author":"Smith","year":"2000","journal-title":"J Endocrinol"},{"key":"R34-3-20210119","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.amjcard.2003.09.051","article-title":"Comparison of effects on left ventricular filling pressure of intravenous nesiritide and high-dose nitroglycerin in patients with decompensated heart failure.","volume":"93","author":"Elkayam","year":"2004","journal-title":"Am J Cardiol"},{"key":"R35-3-20210119","doi-asserted-by":"crossref","first-page":"1328","DOI":"10.1016\/j.jacc.2004.06.015","article-title":"Primary results of the Rapid Emergency Department Heart Failure Outpatient Trial (REDHOT) A multicenter study of B-type natriuretic peptide levels, emergency department decision making, and outcomes in patients presenting with shortness of breath.","volume":"44","author":"Maisel","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R36-3-20210119","first-page":"1531","article-title":"Intravenous nesiritide vs nitroglycerin for treatment of decompensated congestive heart failure: a randomized controlled trial.","volume":"287","year":"2002","journal-title":"JAMA"},{"key":"R37-3-20210119","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1056\/NEJMoa020233","article-title":"Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure.","volume":"347","author":"Maisel","year":"2002","journal-title":"N Engl J Med"},{"key":"R38-3-20210119","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1067\/mhj.2002.125623","article-title":"A rapid B-type natriuretic peptide assay accurately diagnoses left ventricular dysfunction and heart failure: a multicenter evaluation.","volume":"144","author":"Wieczorek","year":"2002","journal-title":"Am Heart J"},{"key":"R39-3-20210119","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1056\/NEJMoa031681","article-title":"Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea.","volume":"350","author":"Mueller","year":"2004","journal-title":"N Engl J Med"},{"key":"R40-3-20210119","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1067\/mem.2002.121483","article-title":"B-type natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnea.","volume":"39","author":"Harrison","year":"2002","journal-title":"Ann Emerg Med"},{"key":"R41-3-20210119","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/j.jacc.2004.05.071","article-title":"Prognostic role of b-type natriuretic peptide levels in patients with type 2 diabetes mellitus.","volume":"44","author":"Bhalla","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R42-3-20210119","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/j.ejheart.2003.12.011","article-title":"Biological variation of the natriuretic peptides and their role in monitoring patients with heart failure.","volume":"6","author":"Wu","year":"2004","journal-title":"Eur J Heart Fail"},{"key":"R43-3-20210119","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1016\/j.amjcard.2004.02.072","article-title":"Optimum blood collection intervals for B-type natriuretic peptide testing in patients with heart failure.","volume":"93","author":"Wu","year":"2004","journal-title":"Am J Cardiol"},{"key":"R44-3-20210119","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1054\/jcaf.2001.23355","article-title":"A rapid test for B-type natriuretic peptide correlates with falling wedge pressures in patients treated for decompensated heart failure: a pilot study.","volume":"7","author":"Kazanegra","year":"2001","journal-title":"J Card Fail"},{"key":"R45-3-20210119","doi-asserted-by":"crossref","first-page":"3184","DOI":"10.1161\/01.CIR.94.12.3184","article-title":"Hemodynamic and renal excretory effects of human brain natriuretic peptide infusion in patients with congestive heart failure A double-blind, placebo-controlled, randomized crossover trial.","volume":"94","author":"Marcus","year":"1996","journal-title":"Circulation"},{"issue":"suppl 4","key":"R47-3-20210119","first-page":"S10","article-title":"B-type natriuretic peptide measurements in diagnosing congestive heart failure in the dyspneic emergency department patient.","volume":"3","author":"Maisel","year":"2002","journal-title":"Rev Cardiovasc Med"},{"key":"R48-3-20210119","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1016\/j.jacc.2003.10.066","article-title":"Obesity and suppressed B-type natriuretic peptide levels in heart failure.","volume":"43","author":"Mehra","year":"2004","journal-title":"J Am Coll Cardiol"},{"key":"R49-3-20210119","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1161\/01.CIR.0000112582.16683.EA","article-title":"Impact of obesity on plasma natriuretic peptide levels.","volume":"109","author":"Wang","year":"2004","journal-title":"Circulation"},{"key":"R50-3-20210119","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/ajkd.2003.50118","article-title":"B-type natriuretic peptide and renal function in the diagnosis of heart failure: an analysis from the Breathing Not Properly Multinational Study.","volume":"41","author":"McCullough","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"R51-3-20210119","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1161\/01.CIR.0000025242.79963.4C","article-title":"B-type natriuretic peptide and clinical judgment in emergency diagnosis of heart failure: analysis from Breathing Not Properly (BNP) Multinational Study.","volume":"106","author":"McCullough","year":"2002","journal-title":"Circulation"},{"key":"R52-3-20210119","first-page":"S26","article-title":"Early initiation of intravenous vasoactive therapy improves heart failure outcomes: an analysis from the ADHERE registry database [Abstract].","volume":"42","author":"Peacock","year":"2003","journal-title":"Ann Emerg Med"},{"key":"R54-3-20210119","article-title":"Natrecor [package insert].","year":"2004"},{"key":"R55-3-20210119","doi-asserted-by":"crossref","first-page":"47","DOI":"10.2165\/00003495-200363010-00004","article-title":"Nesiritide: A review of its use in acute decompensated heart failure.","volume":"63","author":"Keating","year":"2003","journal-title":"Drugs"}],"container-title":["Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.hpc.0000155219.26524.19","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T20:26:44Z","timestamp":1621888004000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00132577-200503000-00003"}},"subtitle":["Diagnostic, Prognostic, and Therapeutic Use"],"short-title":[],"issued":{"date-parts":[[2005,3]]},"references-count":51,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2005]]}},"URL":"https:\/\/doi.org\/10.1097\/01.hpc.0000155219.26524.19","relation":{},"ISSN":["1535-282X"],"issn-type":[{"value":"1535-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2005,3]]}}}